Illumina Inc. focuses on genomics growth as a leading Nasdaq-listed life sciences company
Published on 07/09/2026 at 12:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Illumina Inc. (ISIN US4523271090) is one of the best-known providers of genomic sequencing and array-based technologies, with its stock listed on Nasdaq and widely followed by investors who focus on the long-term growth of precision medicine and data-driven healthcare.
Genomics leader with a Nasdaq listing
Illumina Inc. is headquartered in the United States and its shares trade on Nasdaq, which anchors the company firmly in the US equity market and makes it part of the broader life sciences and biotechnology investment universe.
The company has built its business around high-throughput sequencing systems, consumables, and data analytics tools that enable researchers and clinicians to decode DNA and RNA at scale, helping to power academic research, pharmaceutical development, and clinical applications such as oncology testing and rare disease diagnosis.
Business focus on sequencing and clinical applications
Illumina Inc.'s core business model centers on selling sequencing instruments, flow cells, reagents, and related software to laboratories, hospitals, and research institutions, often under multi-year purchasing and service arrangements that support recurring revenue streams.
Over time, the company has expanded its focus from purely research-oriented customers to clinical and applied markets, where genomic information is used to guide cancer therapies, reproductive health decisions, infectious disease surveillance, and population genomics programs run by health systems and governments.
Learn more about Illumina Inc.
For additional company information, background, and regulatory disclosures on Illumina Inc., further resources are available online beyond this article.
Key sequencing platforms and consumables
One of Illumina Inc.'s representative product families is its line of high-throughput next-generation sequencing platforms, which are designed to process large volumes of DNA samples with high accuracy and efficiency.
These systems typically work in tandem with Illumina-branded consumables, including flow cells and reagent kits, and are supported by integrated informatics solutions that help laboratories manage sample workflows, quality control, and bioinformatics analysis.
Illumina Inc. stock and market context
Illumina Inc. stock trades in US dollars on Nasdaq, reflecting its role as a US-listed life sciences and genomics company with global operations and customers.
Illumina Inc. - key facts for investors
- Company: Illumina Inc.
- ISIN: US4523271090
- Ticker: ILMN
- Exchange: Nasdaq
- Sector / Industry: Health care - life sciences tools and services
- Index membership: Major US health care and life sciences indices where applicable
- Next earnings date: Typically scheduled on a quarterly basis and announced through company communications
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
